Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $235.96 USD
Change Today +3.00 / 1.29%
Volume 642.5K
SHPG On Other Exchanges
Symbol
Exchange
SHPG is not on other exchanges.
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Riverwalk

Citywest Business Campus

Dublin, 24

Ireland

Phone: 353 1 429 7700

Fax:

ce diagnosis is confirmed, patients are usually treated for life. The first line treatment for inflammatory bowel disease is mesalamine (5-aminosalicylic acid (5-ASA)) based products. LIALDA/MEZAVANT LIALDA is indicated in the United States and Canada for the induction of remission in patients with mild to moderately active UC and for the maintenance of remission of UC. The addition of the indication for maintenance of remission of UC was approved by Health Canada in 2011 and by the FDA in 2011. LIALDA is the first and only FDA-approved once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. LIALDA contains the highest commercially available mesalamine dose per tablet (1.2g), so patients can take as few as two tablets once daily. As of December 31, 2014, LIALDA/MEZAVANT was commercially available in 19 countries either directly or through distributor arrangements. LIALDA is marketed in certain territories outside the United States by the company under the trade name MEZAVANT and MEZAVANT XL. PENTASA PENTASA controlled release capsules are marketed by the company in the United States and are indicated for the induction of remission and for the treatment of patients with mild to moderately active UC. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the United States in 250mg and 500mg capsules. In 2012, the FDA issued draft bioequivalence guidelines for generic approvals of orally-delivered delayed or extended-release mesalamine-based drugs (including LIALDA and PENTASA). Treatments for Chronic Constipation Chronic idiopathic constipation is a widespread and often debilitating disorder. The constipated patient population can be split into three distinct groups, such as patients with primary constipation (without other underlying diseases or not caused by use of medication); patients constipated as a result of regular use of medication, such as opioids; and patients with severe constipation resulting from neurodegenerative disorders, such as multiple sclerosis and Parkinson’s disease. RESOLOR RESOLOR is the first of a new generation of selective, high-affinity 5-HT4 receptor agonists that stimulates gastrointestinal motility and acts primarily on different parts of the lower gastrointestinal tract (prokinetic). RESOLOR is available in 1mg and 2mg dose strengths, both for once-daily dosing. As of December 31, 2014, RESOLOR was available in 18 the EU countries. Treatments for Rare Diseases REPLAGAL REPLAGAL is marketed for the treatment of Fabry disease outside of the United States. Fabry disease is a rare, inherited genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats. The signs and symptoms of Fabry disease vary widely from patient to patient, the most common include severe pain of the extremities, impaired kidney function, which often progresses to kidney failure, early heart disease, stroke, and disabling gastrointestinal symptoms. REPLAGAL is a fully human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with an active enzyme to ameliorate certain clinical manifestations of Fabry disease. As of December 31, 2014, REPLAGAL was approved in 46 countries excluding the United States. ELAPRASE ELAPRASE is a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II). Hunter syndrome is a rare, inherited genetic disorder mainly affecting males that interferes with the body's ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans or GAGs. In patients with Hunter syndrome, cumulative build-up of GAGs in cells throughout the body interferes with the way certain tissues and organs function, leading to severe clinical complications and early mortality. ELAPRASE was approved by the FDA in 2006 and granted marketing authorization by the EMA in 2007 for the long term t

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $235.96 USD +3.00

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$92.62 AUD -0.13
Eisai Co Ltd ¥8,045 JPY +331.00
Hospira Inc $89.93 USD +0.01
Mylan NV $50.37 USD -1.12
Perrigo Co PLC $185.42 USD -2.77
View Industry Companies
 

Industry Analysis

SHPG

Industry Average

Valuation SHPG Industry Range
Price/Earnings 14.9x
Price/Sales 7.3x
Price/Book 5.0x
Price/Cash Flow 14.2x
TEV/Sales 7.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.